References
- Gong J H, Maki G, Klingemann H G. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 1994; 8: 652–658
- Keating A, Martin P, Bernstein I, Papayannopoulou T, Raskind W, Singer J. EM-2 and EM-3: Two new Ph + myeloid cell lines. Normal and Neoplastic Hematopoiesis, UCLA Symposia on Molecular and Cellular Biology, D W Golde, P A Marks. Alan R. Liss. Inc., New York 1983; 513–520, New Series 9
- Klingemann H G, Wong E, Maki G. A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood. Biology of Blood and Marrow Transplantation 1996; 2: 68–75
- Mahrus S, Kisiel W, Craik C S. Granzyme M is a regulatory protease that inactivates proteinase inhibitor 9, an endogenous inhibitor of granzyme B. Journal of Biological Chemistry 2004; 279: 54275–54282
- Matsuo Y, Drexler H G. Immunoprofiling of cell lines derived from natural killer-cell and natural killer-like T-cell leukemia-lymphoma. Leukemia Research 2003; 27: 935–945
- Ozdemir O, Ravindranath Y, Savasan S. Cell-mediated cytotoxicity evaluation using monoclonal antibody staining for target or effector cells with annexinV/propidium iodide colabeling by fluorosphere-adjusted counts on three-color flow cytometry. Cytometry 2003; 56A: 53–60
- Raskind W H, Disteche C M, Keating A, Singer J W. Correlation between cytogenetic and molecular findings in human chronic myelogenous leukemia lines EM-2 and EM-3. Cancer Genetics and Cytogenetics 1987; 25: 271–284
- Suck G, Branch D R, Smyth M J, Miller R G, Vergidis J, Fahim S, Keating A. KHYG-1, a model for the study of enhanced natural killer cell cytotoxicity. Experimental Hematology 2005; 33: 1160–1171
- Taguchi Y, Kondo T, Watanabe M, Miyaji M, Umehara H, Kozutsumi Y, Okazaki T. Interleukin-2-induced survival of natural killer (NK) cells involving phosphatidylinositol-3 kinase-dependent reduction of ceramide through acid sphingomyelinase, sphingomyelin synthase, and glucosylceramide synthase. Blood 2004; 104: 3285–3293
- Tam Y K, Maki G, Miyagawa B, Hennemann B, Tonn T, Klingemann H G. Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy. Human Gene Therapy 1999; 10: 1359–1373
- Tam Y K, Martinson J A, Doligosa K, Klingemann H G. Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy. Cytotherapy 2003; 5: 259–272
- Tonn T, Becker S, Esser R, Schwabe D, Seifried E. Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92. Journal of Hematotherapy and Stem Cell Research 2001; 10: 535–544
- Yagita M, Huang C L, Umehara H, Matsuo Y, Tabata R, Miyake M, Konaka Y, Takatsuki K. A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation. Leukemia 2000; 14: 922–930